All News
Filter News
Found 808,679 articles
-
From Patient-Centric Technologies to Clinical Trial Supply Chain Management, CRF Bracket Moves Clinical Trials Forward at the 10th Annual SCOPE Summit
2/12/2019
Running a seamless clinical trial means improving not only data quality but also operational logistics and most importantly the patient experience.
-
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
2/12/2019
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 Increasing confidence in bemcentinib safety profile with more than 250 patients dosed
-
Bio-Rad to Report Fourth-Quarter and Full-Year 2018 Financial Results Thursday, February 28, 2019
2/12/2019
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2018 on Thursday, February 28, 2019, following the close of the market.
-
Author Rahaf Harfoush Addresses Epidemic of Work Burnout in New Book: 'Hustle & Float: Reclaim Your Creativity and Thrive in a World Obsessed With Work'
2/12/2019
Unraveling our cultural obsession with hustling: Why our fanatical pursuit of productivity is hurting our creative performance.
-
Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
2/12/2019
Axonics Modulation Technologies, Inc. announced the submission of complete test data to the U.S. Food & Drug Administration for the purpose of gaining Conditional Full Body Magnetic Resonance Imaging labeling approval for the Axonics r-SNM® System1 for urinary and bowel dysfunction.
-
More than 150 Companies Adopt Veeva Vault RIM Applications to Streamline Regulatory Processes
2/12/2019
Veeva Systems (NYSE:VEEV) today announced increasing numbers of life sciences companies are adopting applications in Veeva Vault RIM, the first unified suite of RIM applications on one cloud platform, to modernize their regulatory processes and systems.
-
GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology
2/12/2019
Intravitreal administration of GS010 in patients with LHON was safe and well tolerated
-
Health Canada Keynote at the 17th Cold Chain Global Forum Canada
2/12/2019
IQPC is pleased to announce the new Keynote speaker for the 17th Cold Chain Global Forum Canada!
-
Trialbee Signs Two Top Ten Pharmaceutical Companies for Its Patient-Matching and Engagement Platforms
2/12/2019
Trialbee, a world leading technology provider in patient matching and engagement announces two commercial milestones with two of the top 10 pharma companies.
-
Notice to the media - Government of Canada to Announce Funding for Gender-Based Violence Prevention
2/12/2019
On behalf of the Honourable Ginette Petitpas Taylor, Federal Minister of Health, Peter Fragiskatos, Member of Parliament, will announce federal support for gender-based violence prevention.
-
Sanofi and Regeneron, following Amgen dropping the price of Repatha in October 2018, have dropped Praluent to $5,850 a year. This is about a 60-percent reduction from the original price for both the 75 mg and 150 mg doses. The new prices will kick in early March.
-
AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.
-
IFM Therapeutics is launching its second subsidiary in less than a year. This morning, the Boston-based company, launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases like NASH, lupus and Parkinson’s.
-
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Hea...
-
NAD Boosters: Promising in Mice for Anti-Aging and Alzheimer's, but Not Yet Ready for Prime-time
2/11/2019
There has been recent optimism—and possibly hype—over so-called NAD boosters. Kaiser Health News (KHN) recently reported on Harvard University researcher David Sinclair, who is taking his own research product, a supplement that boosts nicotinamide adenine dinucleotide (NAD), a cofactor found in a... -
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
-
When the U.S. Food and Drug Administration approved Genentech’s Xofluza, a single-dose treatment for the flu, it was met with great fanfare, particularly in Japan, where the treatment was first discovered.
-
When biotech companies post openings for new positions, hiring managers often face the immense task of sorting through numerous resumes of qualified candidates. However, in South Korea, hiring managers are facing a different problem – a dearth of qualified candidates.
-
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
-
OWC Pharmaceutical Research Corp, Letter to Shareholders - February 11, 2019
2/11/2019
OWC Pharmaceutical Research Corp., a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, issued a letter to shareholders.